New (S)-verbenone-isoxazoline-1,3,4-thiadiazole hybrids: synthesis, anticancer activity and apoptosis-inducing effect.
Fiche publication
Date publication
septembre 2023
Journal
Future medicinal chemistry
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MORJANI Hamid
Tous les auteurs :
Fawzi M, Bimoussa A, Laamari Y, Oussidi AN, Oubella A, Ketatni EM, Saadi M, Ammari LE, Morjani H, Ait Itto MY, Auhmani A
Lien Pubmed
Résumé
This study aimed to develop novel isoxazoline-1,3,4-thiadiazole hybrids from (S)-verbenone for potential anticancer treatment, particularly focusing on cytotoxic and apoptotic effects in hormone-sensitive MCF-7 and triple-negative MDA-MB-231 breast cancer cells. (S)-verbenone was used to synthesize hybrids through 1,3-dipolar cycloaddition, followed by thorough characterization. The compounds were screened across cancer cell lines, showing significant anticancer effects. Compound 8b notably induced apoptosis via the caspase-3/7 pathway and cell cycle arrest, displaying noteworthy cytotoxicity against MCF-7 and MDA-MB-231 cells. These findings underscore the potential of (S)-verbenone isoxazoline-1,3,4-thiadiazole derivatives for breast cancer therapy due to their remarkable apoptotic activity. This study highlights a promising avenue for advancing breast cancer treatment using these derivatives, founded on (S)-verbenone, showcasing their distinct potential for inducing apoptosis.
Mots clés
(S)-verbenone, 1,3,4-thiadiazole, apoptosis, breast cancer, caspase 3/7, hormone sensitive, hybridization, triple negative
Référence
Future Med Chem. 2023 09 29;: